Reproductive medicine involving genome editing: clinical uncertainties and embryological needs  by Ishii, Tetsuya
Commentary
Reproductive medicine involving genome editing:
clinical uncertainties and embryological needs
Tetsuya Ishii *
Ofﬁce of Health and Safety, Hokkaido University, Sapporo 060-0808, Japan
A B S T R A C T
Genome editing based on site-directed nucleases facilitated efﬁcient and versatile genetic modiﬁcations in human cells. However, recent reports, dem-
onstrating CRISPR/Cas9-mediated genome editing in human embryos have raised profound concerns worldwide. This commentary explores the clinical
justiﬁcation and feasibility of reproductive medicine using germline genome editing. Despite the perceived utility of reproductive medicine for treating
intractable infertility, it is difﬁcult to justify germline genome editing from the perspective of the prospective child. As suggested by the UK legalization
regarding mitochondrial donation, the prevention of genetic disease in offspring by genome editing might be acceptable in limited cases of serious or
life-threatening conditions, where no alternative medicine is available. Nonetheless, the mosaicism underlying human embryos as well as the off-
target effect by artiﬁcial nucleases will likely hamper preimplantation genetic diagnosis prior to embryo transfer. Such considerations suggest that
this type of reproductive medicine should not be developed toward a clinical application. However, the clinical uncertainties underscore the need for
embryology that can address fundamental questions regarding germline aneuploidy and mosaicism using genome editing.
© 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
The genetic modiﬁcation of germ cells or zygotes (germline) can impact
the entire body of the progeny as well as subsequent generations via
modiﬁed germ cells. For this reason, germline genetic modiﬁcation
has been considered to be effective against some genetic diseases.
Transferring donor oocyte-derived cytoplasm (containing mitochon-
drial DNA (mtDNA)) to putatively non-viable oocytes or zygotes was
practised in cases of unexplained infertility from the late 1990s to the
early 2000s. However, such cytoplasmic transfers resulted in preg-
nancies affected with Turner syndrome (Barritt et al., 2001b), fetal
deaths (Zhang, 2003) and the onset of pervasive developmental sisorder
in progeny (Barritt et al., 2001b). Conversely, the UK has recently
become the ﬁrst country to allow the clinical use of karyoplast trans-
fer to an enucleated donor oocyte or zygote (so-called mitochondrial
donation) in order to prevent the inheritance of pathogenic mtDNA
mutations in offspring (HFEA, 2015).
Genome editing tools, such as zinc-ﬁnger nucleases (ZFN), tran-
scription activator-like effector nucleases (TALEN) and the clustered
regularly interspaced short palindromic repeat (CRISPR)/Cas9, have fa-
cilitated the insertion of an exogenous gene, correcting a genemutation
(or copying of a variant) and disrupting an endogenous gene in human
cells. The artiﬁcial, site-directed nucleases can unintentionally break
DNA double strands at non-target sites (Ishii, 2015b; Kim and Kim, 2014),
although a recent clinical trial concluded that the infusion of T cellsmodi-
ﬁed by ZFN is safe in HIV-positive patients, despite no investigation of
off-target mutations in the infused cells (Tebas et al., 2014). With regard
to germline genome editing, two groups recently reported that the mi-
croinjection of CRISPR/Cas9 into tripronuclear zygotes can produce
human embryos with an intentional genetic modiﬁcation, but also in-
dicated three technical problems: low efﬁciency of on-target gene
modiﬁcation, off-target mutations and the mosaicism of genetic modi-
ﬁcation in the embryos (Kang et al., 2016; Liang et al., 2015). More
recently, a non-human primate (NHP) study demonstrated that the mi-
croinjection of optimized ZFN/TALEN into zygotes can avoid the
mosaicism of genetic modiﬁcation in resultant monkeys, causing them
to display immune-deﬁciency similar to human patients (Sato et al., 2016).
These reports suggest that reproductive medicine involving genome
editing is theoretically feasible although there are still concerns re-
garding the safety and efﬁcacy related to its clinical use. However, the
two human embryo editing studies raised serious concerns over its
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medical use and non-medical (social) use worldwide, prompting several
global discussions such as the International Summit on Human Gene
Editing (NASEM, 2015).
The present commentary discusses the two objectives of repro-
ductive medicine involving germline genome editing: infertility
treatment and disease prevention. Then, the clinical feasibility of such
reproductive medicine is examined in terms of risk assessment. In
addition, the wider implications of the ﬁndings are discussed in sci-
entiﬁc contexts.
Infertility treatment
According to the latest report on the treatments involving assisted re-
productive technology by the European Society of Human Reproduction
and Embryology, pregnancy rates in 2011, while the overall number of
assisted reproductive technology cycles has continued to increase, de-
creased slightly to those reported in 2010. For all IVF cycles, the clinical
pregnancy rates per aspiration and per transfer were stable with 29.1
and 33.2%, respectively. Moreover, for intracytoplasmic sperm injec-
tion (ICSI), the corresponding rates were stable with 27.9 and 31.8%,
respectively (Calhaz-Jorge et al., 2016). To enhance the assisted re-
productive technology success rate, personalization is one of future
directions (Simon, 2013). Since half of idiopathic infertility cases are con-
sidered to have a genetic basis (Singh and Schimenti, 2015), there is a
tremendous need for personalized reproductive medicine, which may
be achieved by correcting a mutation responsible for infertility through
genome editing (Ishii, 2015a). For instance, human oocytes with a mis-
sense mutation in the TUBB8 undergo developmental arrest after
fertilization (Feng et al., 2016b). Currently, two relevant reports are avail-
able. In 2016, the ﬁrst case report identiﬁed seven TUBB8 mutations
that were responsible for oocytemeiosis I arrest in seven of the 24 fami-
lies, using exome sequencing (Feng et al., 2016a). The second report
discovered nine new TUBB8 mutations in 10 patients from nine fami-
lies, displaying phenotypic variability (Feng et al., 2016b). Among them,
oocytes having any of three missense mutations (I210V, T238M and
N348S) are of particular note. Such oocytes could extrude the ﬁrst polar
body and could be fertilized, despite subsequent developmental arrest.
Genome editing-mediated TUBB8 correction in premature oocytes, such
as GV stage oocytes, could recover their developmental potential, al-
though the remaining transcripts from mutated TUBB8 could disturb
the formation of microtubule via de-novo synthesis of the functional
protein. It should also be noted that genome editing-mediated gene cor-
rection has not been demonstrated in mammalian oocytes.
Moreover, TEX11 mutations cause meiotic arrest and azoosper-
mia in infertile males (Yatsenko et al., 2015). If spermatogonial stem
cells (SSC) can be retrieved from the patient’s testis, viable sper-
matozoa could be generated from genetically corrected SSC in vitro
in the near future (Ishii, 2015a; Ishii and Pera, 2016). Of note, a recent
report demonstrated that rat offspring were born using spermato-
zoa regenerated following the transplantation of CRISPR/Cas9-
modiﬁed SSC (Chapman et al., 2015), although SSC transplantation
is still experimental in humans.
However, its use is currently unjustiﬁable. First, genetic modiﬁ-
cation in humans is still in the early stages. Although at least 2356
clinical trials of somatic gene therapy have been conducted world-
wide, fewer than 10 products have gone on to be approved (JGM, 2016).
Second, very few cases of the clinical use of human germline genetic
modiﬁcation have been reported. Only ooplasmic transfer and pro-
nuclear transfer were practised for treating intractable infertility by
transferring donor oocyte-cytoplasm to a patient’s oocyte, or by trans-
ferring karyoplast including pronuclei to an enucleated donor zygote
(Barritt et al., 2001a; Ishii, 2015b; Zhang, 2003). Third, such cytoplas-
mic transfers are suspected to have imposed congenital anomalies
upon resultant children in some cases. Ooplasmic transfer resulted
in pregnancies affected with Turner syndrome, and the onset of Per-
vasive Developmental Disorder after birth, pronuclear transfer led
to fetal deaths (Barritt et al., 2001b; Zhang, 2003). With regard to oo-
plasmic transfer, the Food and Drug Administration discussions in
2002 suggested that the cytoplasmic transfer caused inappropriate
mitochondrial distribution in oocytes that led to such congenital anoma-
lies. Given that germline genome editing can potentially affect progeny
with the substantial risk of off-target effects, its development for in-
fertility treatment, which will likely promote its widespread use, should
be avoided from the perspective of the prospective child’s welfare.
Disease prevention
Assisted reproductive techniques are practised with prior consent by
parents. However, widely accepted assisted reproductive tech-
niques such as IVF involve no intentional genetic intervention.
Therefore, under what conditions does parental consent justify the
germline genetic intervention from the viewpoint of a child’s welfare?
Consider the UK regulatory framework onmitochondrial transfer
(HFEA, 2015). Such intervention is deemed legal provided the germline
modiﬁcation focusesmtDNA (not nuclear DNA) and intends to prevent
the maternal transmission of ‘serious’ mitochondrial disease to off-
spring. This is employedwhen amother carries the risk of transmitting
the disease to the child. Its practice is limited to serious conditions
among various forms ofmitochondrial disease. Similarly, disease pre-
vention via germline genome editing might be accepted in some
countries.Notably, in the International Summit onHumanGeneEditing,
mitochondrial disease was addressed as a candidate for germline
genome editing (NASEM, 2015). Interestingly, the elimination of patho-
genic mtDNA using mito TALEN (mitochondria-targeted nucleases
to selectively reduce mtDNA haplotypes) requires no oocyte dona-
tion,which is indispensable formitochondrial donation in theUK (Reddy
et al., 2015). Aside from cases of serious mitochondrial disease, the
use of germline genome editing seems compelling in cases of deﬁ-
nite inheritanceof a serious or life-threating autosomal genetic disorder
where preimplantation genetic diagnosis (PGD) is inapplicable, such
as autosomal dominant diseases in which one or both parents is ho-
mozygous (e.g. Huntington disease) or autosomal recessive diseases
where both parents are homozygous (e.g. cystic ﬁbrosis) (Ishii, 2015b).
At least four reports have demonstrated that genome editing-
mediated gene correction and the recovery of phenotypes are feasible
in mouse and rat experiments (Ishii, 2015a).
In such rare cases, the beneﬁts of genome editing for a prospec-
tive child is likely to exceed the risks, such as the failure of disease
prevention and off-target mutations (Ishii, 2015a, 2015b). Therefore,
parental consent for germline genome editing might be justiﬁable.
Clinical potential
Genome editing frequently results in precise genetic modiﬁcations
at target sites in the genome, by introducing site-directed
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nucleases into human cells. However, it is important to contem-
plate whether preventive medicine involving genome editing is truly
feasible in clinical settings (Figure 1).
The introduction of nucleases manifests cytotoxicity against
human embryos, potentially reducing the number of viable embryos
(Kang et al., 2016; Liang et al., 2015). Applying mito TALEN to
oocytes may fail to eliminate aberrant mtDNA under the threshold
level of disease onset. In cases of autosomal dominant diseases,
the microinjection of nucleases into zygotes may fail to correct
bi-allelic mutations at the one-cell stage. Furthermore, the micro-
injection may also lead to mosaicism of genetic modiﬁcation in the
resultant embryos if gene correction initiates at the two-cell or
later stages (Kang et al., 2016; Liang et al., 2015). Furthermore, the
artiﬁcial nucleases could break DNA double strands at off-target
sites for reasons such as the improper selection of a target se-
quence. Subsequently, off-target double-strand breaks could induce
large-scale genomic alternations such as translocations, inver-
sions and large deletions in addition to small insertions or deletions
(indels) of various lengths, including point mutations (Kim and Kim,
2014; Liang et al., 2015). Although the above-mentioned concerns
have been frequently addressed in somatic cell genome editing,
these are also the case in the germline.
As the NHP experiment demonstrated, such risks are expected
to be reduced by the careful design of the guiding molecule (zinc-
ﬁnger domains in ZFN, TALE in TALEN and guide RNA in CRISPR/
Cas9) and prior proﬁling of genome-wide off-target effect (Sato et al.,
2016). However, the risks with genome editing will be substantial in
clinical settings because the subjects are of human origin, not labo-
ratory animals (Kang et al., 2016; Liang et al., 2015). Therefore, PGD
following genome editing is mandatory prior to embryo transfer (Ishii,
2015a). PGD using a single blastomere biopsied from cleavage-
stage embryos is common in assisted reproductive technology centres.
However, this diagnosis is performed using the low amount of initial
starting DNA, which might lead to a misdiagnosis for reasons such
as allele drop-out. Instead, PGD should be performed using several
cells biopsied from the trophectoderm at the blastocyst-stage
(SenGupta et al., 2016). This type of PGD can more reliably detect bi-
allelic modiﬁcations without large-scale genomic changes.
Nevertheless, clinical uncertainties may occur in the diagnosis.
First, it would be difﬁcult to detect small indels, including point mu-
tations, arising from off-target effects in the embryonic genome. The
use of next-generation sequencing (NGS), such as whole-genome or
whole-exome sequencing, following whole genome ampliﬁcation (WGA)
is likely to be considered, because the indels created in the promotors
and terminators as well as protein-coding regions may impact the
gene expression and health of resultant children. However, the WGA
introduces artefacts into the sample (SenGupta et al., 2016). Addi-
tionally, it is likely that NGS can hardly distinguish small indels from
a single nucleotide polymorphism (SNP) or spontaneous mutations
(Liang et al., 2015). Furthermore, chromosome instability is common
even in embryos derived from young fertile women. In addition to mo-
saicism for whole chromosome aneuploidies and uniparental disomies,
segmental chromosomal imbalances frequently occur in cleavage-
stage embryos (Vanneste et al., 2009). The microinjection of artiﬁcial
nucleases into human embryos with chromosomal instability may also
increase the rate of chromosomal breakage and aneuploidy via off-
target effects. The aberrant genomic constitutions and mosaicism are
likely to produce misleading PGD results in blastocyst-stage embryos.
Even if PGD can conﬁrm that the biopsied trophectoderm cells have
corrected genes and no signiﬁcant chromosomal abnormalities, the
genetic condition in the inner cell mass (ICM) may be different from
that of the biopsied cells (Taylor et al., 2014).
Such considerations suggest the difﬁculties in risk assessment
following germline genome editing in clinics. Nonetheless, one might
assert that clinical management using amniotic diagnosis or chori-
onic villus sampling can be performed after embryo transfer and
subsequent pregnancy since the beneﬁts of genome editing will be
likely to exceed the risks. However, the reproductive medicine may
Figure 1 – The clinical uncertainties in reproductive medicine involving genome editing. This medicine is initiated by microinjecting
artiﬁcial nucleases into human embryos. Subsequently, preimplantation genetic diagnosis (PGD) is carried out to investigate on-target
modiﬁcations and no signiﬁcant off-target effects (large genomic alternations and small indels). In dotted-line boxes, potential risks in
each procedure are indicated. Bold-line boxes show the factors underlying the human germline, which will impact genome editing as well
as PGD. ICM = inner cell mass; TE = trophectoderm.
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fail to prevent the onset of certain diseases in offspring due to chro-
mosomal mosaicism in the ICM. As the two reports on the CRISPR/
Cas9 treatment of tripronuclear zygotes (Kang et al., 2016; Liang et al.,
2015), genome editing may result in low efﬁciency of gene correc-
tion in the polysomic cells, whichmay lead to the onset of an autosomal
dominant disease in offspring. Additionally, the resultant offspring may
still be affected, or develop another disease after birth, in childhood
or adulthood. Indeed, recent mouse studies have shown that off-
spring who underwent embryo biopsy are at a high risk of late-
onset neurodevelopmental and metabolic diseases (Sampino et al.,
2014; Yu et al., 2009).
Scientiﬁc implications
The aforementioned analysis also identiﬁed the lack of fundamental
knowledge regarding mosaicism, which has been suggested to be as
high as 70% and 90% in cleavage- and blastocyst-stage embryos
derived from IVF, respectively (Taylor et al., 2014). Whole chromo-
some imbalances may arise due to the meiotic error. After fertilization,
mitotic error can also cause chromosomal breakage fusion-bridge
cycles, resulting in complex patterns of segmental aneuploidy at the
cleavage stage (Vanneste et al., 2009). Simultaneously, such aneu-
ploidies might be in part self-corrected, resulting in themosaic embryo
(Barbash-Hazan et al., 2009; Munne et al., 2005). Meanwhile, mitotic
error at the cleavage stage can by itself lead to general or conﬁned
mosaicism at the blastocyst stage (Taylor et al., 2014).
It is scientiﬁcally and clinically essential to address questions about
when, where and how aneuploidy, its self-correction and mosa-
icism arise in the human germline. Genome editing is useful in such
embryological studies. For instance, EGFP-dead Cas9 (inactive form
of enzyme) fusion can be used tomap hot spots of chromosomal break-
age through the visualization of loci harbouring repetitive sequences,
such as telomeres (Chen et al., 2013). With regard to self-correction,
previous studies have suggested that the actual fetus only derives from
three cells of the ICM, whereas chromosomally abnormal cells can
be forced away from the inner cell mass (Taylor et al., 2014). How
then is the cell fate determined in human embryogenesis? In mouse
embryos at the 8-cell stage, the polarized cells have actomyosin and
an apical domain enriched with ‘certain proteins’ (Plusa and
Hadjantonakis, 2016). As cells divide asymmetrically, one daughter
cell with the apical domain becomes low contractile, whereas the other
cell abundant in actomyosin becomes highly contractile. A gene-
expression activated by Yap guides the low contractile cell to
trophectoderm at the 32-cell stage. Highly contractile cells become
the ICM. Certain proteins at the apical domain may be found using
the SLENDER (single-cell labeling of endogenous proteins by
CRISPRCas9-mediated homology-directed repair) method, which label
proteins via CRISPR-Cas9-mediated homology-directed repair in em-
bryonic cells (Mikuni et al., 2016). Previous research suggests that
certain culture conditions and/or hormonal stimulation protocols may
impact aneuploidy and subsequent mosaicism (Munne et al., 1997).
In-vitro research using human embryos donated from patients or the
NHP embryos, is expected to provide in-depth insight into aneu-
ploidy and mosaicism by modifying culture conditions and utilizing
CRISPR/Cas9-based platforms. Thus, versatile genome editing is ex-
pected to enhance our knowledge regarding the mosaicism in human
early embryos.
Conclusions
Although genome editing is a robust genetic engineering tool, its
straightforward use is, at present, unfeasible in clinical settings
because our knowledge is still lacking regarding human genetic modi-
ﬁcations as well as the genetics of the human germline. However,
genome editing can be used to obtain fundamental knowledge re-
garding aneuploidy and mosaicisms, which will enhance genetic
counselling to help infertile patients choose among reproductive
options, contribute to clinical management and enhance the as-
sisted reproductive technology success rate.
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